National Cancer Institute (NCI): Lung Neoplasms trials

The registry lists 224 Lung Neoplasms studies with National Cancer Institute (NCI) as lead sponsor. 18 are open to participants now and 84 have results posted.

Early Phase 1 1Phase 1 72Phase 2 118Phase 3 21No phase 32(a study in two phases counts in both)

Studies

Page 2 of 3. Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Carboplatin, Paclitaxel, and Radiation Therapy With or Without Thalidomide in Patients With Stage III Non-small Cell Lung CancerTerminatedNCT00004859Phase 3Results posted
• Carboxyamidotriazole in Treating Patients With Stage III or Stage IV Non-small Cell Lung CancerCompletedNCT00003869Phase 3Results posted
• Testing the Safety of the Anti-cancer Drug, Sn-117m-DTPA, for Advanced Cancers That Have Spread to BonesWithdrawnNCT06982222Phase 1
• Testing the Addition of AZD6738 (Ceralasertib) to Immunotherapy to Increase Time Without Cancer for Patients With Non-Small Cell Lung CancerActive, not recruitingNCT06732401Phase 3
• Study of Front Line Pembrolizumab and Valemetostat in PD-L1 Positive, HPV-Negative Recurrent/Metastatic Squamous Cell Carcinoma (SCC) of the Head and Neck: The PANTHERASWithdrawnNCT05879484Phase 1/2
• Oral Iloprost for the Prevention of Lung Cancer In Former SmokersWithdrawnNCT05411107Phase 2
• Testing the Addition of an Anti-Cancer Drug, TRC102, to the Usual Chemotherapy Treatment (Pemetrexed, Cisplatin or Carboplatin) During Radiation Therapy for Stage III Non-Squamous Non-Small Cell Lung CancerActive, not recruitingNCT05198830Phase 2
• Testing the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy Treatment During Radiation Therapy for Superior Sulcus Non-small Cell Lung CancerWithdrawnNCT04989283Phase 2
• Testing the Addition of Radiation Therapy to the Usual Treatment (Immunotherapy With or Without Chemotherapy) for Advanced Stage Non-small Cell Lung Cancer Patients Who Are PD-L1 NegativeActive, not recruitingNCT04929041Phase 2/3
• Aerosolized Azacytidine as Epigenetic Priming for Bintrafusp Alfa-Mediated Immune Checkpoint Blockade in Patients With Unresectable Pulmonary Metastases From Sarcomas, Germ Cell Tumors, or Epithelial MalignanciesWithdrawnNCT04648826Phase 1/2
• Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial CancerActive, not recruitingNCT04491942Phase 1
• Mobile Sensor Technologies to Assess General Symptomology of People With CancerCompletedNCT04465214
• National Cancer Institute "Cancer Moonshot Biobank"Active, not recruitingNCT04314401
• Study of Radiation Therapy Followed by Atezolizumab in Stage II or III Non-small Cell Lung Cancer PatientsActive, not recruitingNCT04310020Phase 2
• Testing the Addition of the Pill Chemotherapy, Cabozantinib, to the Standard Immune Therapy Nivolumab Compared to Standard Chemotherapy for Non-small Cell Lung CancerActive, not recruitingNCT04310007Phase 2
• Testing the Addition of an Antibody to Standard Chemoradiation Followed by the Antibody for One Year to Standard Chemoradiation Followed by One Year of the Antibody in Patients With Unresectable Stage III Non-Small Cell Lung CancerActive, not recruitingNCT04092283Phase 3
• Testing the Timing of Pembrolizumab Alone or With Chemotherapy as First Line Treatment and Maintenance in Non-small Cell Lung CancerActive, not recruitingNCT03793179Phase 3
• Genetic Analysis of Blood and Tissue Samples From Patients With Advanced Cancer, Moonshot StudyCompletedNCT03707574
• M6620 and Irinotecan Hydrochloride in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by SurgeryActive, not recruitingNCT02595931Phase 1
• Talazoparib in Treating Patients With Advanced or Metastatic Solid Tumors That Cannot Be Removed by Surgery and Liver or Kidney DysfunctionWithdrawnNCT02567396Phase 1
• Osimertinib and Necitumumab in Treating Patients With EGFR-Mutant Stage IV or Recurrent Non-small Cell Lung Cancer Who Have Progressed on a Previous EGFR Tyrosine Kinase InhibitorActive, not recruitingNCT02496663Phase 1
• Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)Active, not recruitingNCT02465060Phase 2
• Iloprost in Preventing Lung Cancer in Former SmokersCompletedNCT02237183Phase 1
• Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)Active, not recruitingNCT02194738Not applicable
• EF5 in Measuring Tumor Hypoxia in Patients With Stage I-III Non-Small Cell Lung CancerCompletedNCT02154399Phase 2
• Erlotinib Hydrochloride in Treating Non-Small Cell Lung Cancer That is Metastatic or Cannot be Removed by Surgery in Patients With HIV InfectionTerminatedNCT02134886Phase 1
• Azacitidine and Entinostat in Treating Patients With Newly Diagnosed Stage IA-IIIA Non-Small Lung Cancer Undergoing SurgeryTerminatedNCT01886573Phase 1
• Rapid Autopsy and Procurement of Cancer TissueTerminatedNCT01851395
• Recombinant Interleukin-15 in Treating Patients With Advanced Melanoma, Kidney Cancer, Non-small Cell Lung Cancer, or Squamous Cell Head and Neck CancerCompletedNCT01727076Phase 1
• GRN1005 for Brain Metastases From Breast or Lung CancerWithdrawnNCT01679743Phase 2
• Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver DysfunctionCompletedNCT01638533Phase 1
• 18F FLT Imaging Studies of Treatment Response for Lung Cancer and ThymomaWithdrawnNCT01610544Phase 2
• -02341066 and PF-00299804 for Advanced Non-Small Cell Lung CancerTerminatedNCT01441128Phase 1
• Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney DysfunctionActive, not recruitingNCT01366144Phase 1
• Veliparib, Cisplatin, and Gemcitabine Hydrochloride in Treating Patients With Advanced Biliary, Pancreatic, Urothelial, or Non-Small Cell Lung CancerTerminatedNCT01282333Phase 1
• Frequency of EGFR Mutations in Latinos/Hispanics With Non-Small Cell Lung CancerCompletedNCT01255150
• RO4929097 and Erlotinib Hydrochloride in Treating Patients With Stage IV or Recurrent Non-small Cell Lung CancerTerminatedNCT01193881Phase 1
• Gamma-Secretase Inhibitor RO4929097 and Cediranib Maleate in Treating Patients With Advanced Solid TumorsCompletedNCT01131234Phase 1
• AMG 102, Pemetrexed Disodium, and Cisplatin in Treating Patients With Malignant Pleural MesotheliomaWithdrawnNCT01105390Phase 2
• A Phase I Trial of SS1 (dsFv) PE38 With Paclitaxel, Carboplatin, and Bevacizumab in Subjects With Unresectable Non-Small Cell Lung AdenocarcinomaCompletedNCT01051934Phase 1
• Cediranib Maleate and Whole Brain Radiation Therapy in Patients With Brain Metastases From Non-Small Cell Lung CancerTerminatedNCT00937482Phase 1
• A Phase I Study of Belinostat in Combination With Cisplatin and Etoposide in Adults With Small Cell Lung Carcinoma and Other Advanced CancersCompletedNCT00926640Phase 1
• Prospective Analysis of Genotypes in Adults Undergoing Therapy for Lung CancerCompletedNCT00923884
• Effect of Talactoferrin in Adults With Non-Small Cell Lung CancerCompletedNCT00923741Phase 1
• A Case-Cohort Study of Hematopoietic Malignancies and Related Disorders and Lung Cancer in Benzene-Exposed Workers in ChinaCompletedNCT00559065
• R-(-)-Gossypol Acetic Acid, Cisplatin, and Etoposide in Treating Patients With Advanced Solid Tumors or Extensive Stage Small Cell Lung CancerCompletedNCT00544596Phase 1
• Smoky Coal Exposure, Genetic Susceptibility, and Lung Cancer in Non-Smoking Women in ChinaCompletedNCT00482118
• Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal CancerCompletedNCT00397384Phase 1
• Radiation Therapy, Bevacizumab, Paclitaxel, and Carboplatin in Treating Patients With Unresectable Stage IIIB or Stage IV Non-Small Cell Lung Cancer at High Risk for Hemoptysis Caused by BevacizumabCompletedNCT00387374Phase 2
• Bevacizumab, Paclitaxel, Carboplatin, and Radiation Therapy to the Chest in Treating Patients With Locally Advanced Non-Small Cell Lung CancerTerminatedNCT00369551Phase 1
• A Nested Case-Control Study of Lung Cancer and Diesel Exhaust Among Non-Metal MinersCompletedNCT00342264
• Construction and Use of Lung Tumor Microarray for the Analysis of Gene Expression in Lung CancerCompletedNCT00340847
• Development of a Biologic Specimen Bank for the Study of Early Markers of Lung Cancer Among Tin Miners in Yunnan, ChinaCompletedNCT00340405
• Genetic Epidemiology of Lung Cancer and SmokingCompletedNCT00340340
• DNA Repair, p53 and Apoptosis Phenotypes in Lung CancerCompletedNCT00339859
• Cisplatin, Irinotecan, and Bevacizumab, in Treating Patients With Small Cell Lung CancerCompletedNCT00118235Phase 2
• Docetaxel With Either Cetuximab or Bortezomib as First-Line Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung CancerCompletedNCT00118183Phase 2
• Sorafenib Tosylate in Treating Patients With Malignant Mesothelioma.CompletedNCT00107432Phase 2
• Erlotinib and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney, Colorectal, Head and Neck, Pancreatic, or Non-Small Cell Lung CancerCompletedNCT00101348Phase 1/2
• Sorafenib in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung CancerCompletedNCT00098540Phase 2
• Vaccine Therapy, Chemotherapy, and Radiation Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed With SurgeryCompletedNCT00091039Not applicable
• Celecoxib and Erlotinib in Treating Former Smokers With Stage IIIB or Stage IV Non-Small Cell Lung CancerCompletedNCT00088959Phase 1
• S0341: Erlotinib in Treating Patients With Advanced Primary Non-Small Cell Lung CancerCompletedNCT00087412Phase 2
• Erlotinib in Treating Patients With Stage I-IIIA Non-Small Cell Lung Cancer Undergoing Surgical ResectionTerminatedNCT00087269Phase 2
• EF5 and Motexafin Lutetium in Detecting Tumor Cells in Patients With Abdominal or Non-Small Cell Lung CancerTerminatedNCT00087191Not applicable
• Romidepsin in Treating Patients With Relapsed Small Cell Lung CancerCompletedNCT00086827Phase 2
• Erlotinib in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung CancerCompletedNCT00085280Not applicable
• Decitabine and Valproic Acid in Treating Patients With Non-Small Cell Lung CancerCompletedNCT00084981Phase 1
• CCI-779 in Treating Patients With Stage IIIB (With Pleural Effusion) or Stage IV Non-Small Cell Lung CancerCompletedNCT00079235Phase 2
• A Phase II Trial of Triapine (NSC #663249) in Combination With Gemcitabine as Second Line Treatment of Non-Small Cell Lung CancerCompletedNCT00077350Phase 2
• Gemcitabine, Carboplatin, and Bortezomib in Advanced or Recurrent Non-Small Cell Lung CancerCompletedNCT00075751Phase 2
• GTI-2040 and Docetaxel in Treating Patients With Recurrent, Metastatic, or Unresectable Locally Advanced Non-Small Cell Lung Cancer, Prostate Cancer, or Other Solid TumorsCompletedNCT00074022Phase 1/2
• Gefitinib in Treating Patients With Metastatic or Unresectable Head and Neck Cancer or Non-Small Cell Lung CancerCompletedNCT00068497Not applicable
• Suramin and Either Docetaxel or Gemcitabine in Treating Patients With Stage IIIB or Stage IV Platinum-Refractory Non-Small Cell Lung CancerCompletedNCT00066768Phase 1
• Immunotoxin Therapy in Treating Patients With Advanced Solid TumorsCompletedNCT00066651Phase 1
• Erlotinib in Treating Patients With Advanced Non-Small Cell Lung Cancer, Ovarian Cancer, or Squamous Cell Carcinoma of the Head and NeckCompletedNCT00063895Phase 1/2
• Erlotinib and Celecoxib in Treating Patients With Stage IIIB or Stage IV Recurrent Non-Small Cell Lung CancerCompletedNCT00062101Phase 2
• Tipifarnib, Gemcitabine, and Cisplatin in Treating Patients With Stage III or Stage IV Non-Small Cell Lung CancerCompletedNCT00055757Phase 2
• Imatinib Mesylate in Treating Patients With Recurrent Small Cell Lung CancerCompletedNCT00052949Phase 2
• Bortezomib Plus Gemcitabine and Carboplatin in Treating Patients With Advanced or Recurrent Non-Small Cell Lung CancerCompletedNCT00052338Phase 1
• Carboplatin and Etoposide With or Without Oblimersen Sodium in Treating Patients With Extensive Stage Small Cell Lung CancerCompletedNCT00042978Phase 2
• Erlotinib and Radiation Therapy Plus Combination Chemotherapy in Treating Patients With Inoperable Stage III Non-Small Cell Lung CancerTerminatedNCT00042835Phase 1
• Combination Chemotherapy, Radiation Therapy, and Gefitinib in Treating Patients With Stage III Non-Small Cell Lung CancerCompletedNCT00040794Phase 2
• Bortezomib in Treating Patients With Advanced Non-small Cell Lung CancerTerminatedNCT00040768Phase 2
• Erlotinib in Treating Patients With Malignant Mesothelioma of the LungCompletedNCT00039182Phase 2
• Monoclonal Antibody Therapy in Treating Patients With Ovarian Epithelial Cancer, Melanoma, Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Non-Small Cell Lung CancerTerminatedNCT00039091Phase 1
• Phase I Study of Gene Induction Mediated by Sequential Decitabine/Depsipeptide Infusion With or Without Concurrent Celecoxib in Subjects With Pulmonary and Pleural MalignanciesCompletedNCT00037817Phase 1
• 7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007)CompletedNCT00031681Phase 1
• Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney DysfunctionCompletedNCT00030498Phase 1
• Gefitinib in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung CancerCompletedNCT00029003Phase 2
• EF5 in Detecting Oxygen Level and Blood Vessels in Tumor Cells of Patients Undergoing Photodynamic Therapy for Intraperitoneal or Pleural CancerTerminatedNCT00028782Not applicable
• Interleukin-12, Paclitaxel, and Trastuzumab in Treating Patients With Solid TumorsCompletedNCT00028535Phase 1
• CCI-779 in Treating Patients With Extensive-Stage Small Cell Lung CancerCompletedNCT00028028Phase 2
• Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Malignant MesotheliomaCompletedNCT00027703Phase 2
• Gefitinib in Treating Patients With Malignant MesotheliomaCompletedNCT00025207Phase 2
• Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Advanced, Metastatic, or Recurrent Non-Small Cell Lung CancerCompletedNCT00021060Phase 2/3
• Combination Chemotherapy and Radiation Therapy With or Without Gefitinib in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed By SurgeryCompletedNCT00020709Phase 3
• Vaccine Therapy in Treating Patients With Metastatic CancerCompletedNCT00020267Phase 1
• FR901228 in Treating Patients With Refractory or Progressive Small Cell Lung Cancer or Non-small Cell Lung CancerCompletedNCT00020202Phase 2
• Paclitaxel and Hyperthermic Perfusion in Treating Patients With Lung Cancer or Lung Metastases That Cannot Be Removed By SurgeryCompletedNCT00020007Phase 1